{
  "drugs": [
    {
      "name": "Drug X",
      "therapeutic_area": "oncology",
      "sentiment": 0.72,
      "news_count": 34,
      "regulatory": ["FDA fast-track designation granted", "EMA priority review ongoing"],
      "rumors": ["Potential acquisition by BigPharma Inc", "Partnership discussions with Asian distributors"]
    },
    {
      "name": "Drug A",
      "therapeutic_area": "cardiology",
      "sentiment": 0.65,
      "news_count": 22,
      "regulatory": ["FDA approval expected Q2 2025"],
      "rumors": ["Generic competition anticipated by 2027"]
    },
    {
      "name": "Drug M",
      "therapeutic_area": "neurology",
      "sentiment": 0.81,
      "news_count": 45,
      "regulatory": ["Breakthrough therapy designation", "Accelerated approval pathway"],
      "rumors": ["Positive Phase 3 results expected", "Premium pricing strategy being considered"]
    }
  ]
}
